Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the ...

Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly ...

Cell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change ...

Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA ...

It’s easy to assume that more data = better models = faster identification. With AI, you can extract associations between ...

A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.

Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese ...

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved ...